Production Criteria in the Development of a K562-Based Vaccine Platform

by R. Ripley, N. Mahesh, W. Press, J-S. Lee, E. Aguilar-Cordova, and E.J. Beecham
Volume 1, Issue 3 (Fall 2002)

The K562 cell line is a human myelogenous leukemic cell which has been used by several groups, including ours, as a vehicle for cell-based vaccines and immuno-gene therapies. The attractiveness of K562 cells is the ease with which they can be cultured, plus the fact that they express very low levels of MHC proteins. Low MHC expression facilitates the use of these cells in patients with different MHC backgrounds, and it may improve the in vivo survival of the cells by delaying immune rejection. Based largely on these properties, we have been developing the K562 cell line as a universal platform for expressing cytokines, tumor antigens, and other immuno-modulating proteins...

Citation:
Ripley R, Mahesh N, Press W, Lee J-S, Aguilar-Cordova E, Beecham EJ. Production Criteria in the Development of a K562-Based Vaccine Platform. BioProcess J, 2002; 1(3): 31-35.